[
  {
    "objectID": "resources.html",
    "href": "resources.html",
    "title": "Resources",
    "section": "",
    "text": "Websites of interest\n\nASGCT - American Society of Gene & Cell Therapy.\nFDA Cellular & Gene Therapy Products\nFDA Cellular & Gene Therapy Guidances\nEMA Guidelines\n\nSee also the publications tab."
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications of the group",
    "section": "",
    "text": "Here we list the publications that the group has written or contributed to.\n\nAccepted or published\nLi, D., Xu, Z., Wen, S., Ananthakrishnan, R., Kim, Y., Rantell, K.R., Anderson, P., Whitmore, J. and Chiang, A., 2024. Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective. Therapeutic Innovation & Regulatory Science, pp.1-14. | doi |\nMcIntosh, A. and Sverdlov, O. eds., 2024. Development of Gene Therapies: Strategic, Scientific, Regulatory, and Access Considerations. CRC Press.\n\n\nSubmitted"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About This Website",
    "section": "",
    "text": "Website for successR.\nIndex file to build website is _site.yml.\nUse rmarkdown::render_site() or click on “Build” –&gt; “Build site” to build the website.\nSee https://bookdown.org/yihui/rmarkdown/rmarkdown-site.html for background information."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Cell and Gene Therapy working group",
    "section": "",
    "text": "Welcome to the homepage of American Statistical Association (ASA) Cell and Gene Therapy Scientific Working Group (SWG)!\nGenetically engineered cell and gene therapies (CGT) constitute a powerful new class of therapeutic agents that offer hope for curative responses in patients with devastating diseases. Although the U.S. Food and Drug Administration has approved multiple CGT products for cancer and rare disease indications, the current development of CGT still presents several unique statistical challenges. These include small sample sizes, design of dose finding studies to optimize dose selection, identification of patient subgroups in heterogeneous patient populations and treatment response, study design to assess long-term therapeutic safety and benefits, implementation of the estimand framework, linking clinical trial data to real world evidence to provide a comprehensive view of a patient’s journey, innovative randomized phase 3 study design, and manufacturing related issues. To overcome these challenges and advance the field of CGT, it is critical to bring together a collective group of statistical experts to collaborate on sharing experiences and developing strategic solutions to improve patient outcomes.\nFor more information or to get involved in CGT SWG, please contact one of the co-chairs:\nAlan Chiang, Lyell (achiang@lyell.com)\nZhenzhen Xu, FDA (zhenzhen.xu@fda.hhs.gov or zxu@post.harvard.edu)\nDaniel Li, BMS (daniel.li1@bms.com)\n\nLink to this page\nLink to this page: &lt;&gt;."
  },
  {
    "objectID": "subteams.html",
    "href": "subteams.html",
    "title": "Sub-teams",
    "section": "",
    "text": "Lead: Shihua Wen (Novartis)\nObjective: NA\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nZhenzhen\nXu\nFDA\n\n\nKhadija\nRantell\nMHRA\n\n\nLina\nYang\nNovartis\n\n\nShihua\nWen\nNovartis\n\n\nYeonhee\nNA\nNA"
  },
  {
    "objectID": "subteams.html#real-world-evidencereal-world-data-rwerwd",
    "href": "subteams.html#real-world-evidencereal-world-data-rwerwd",
    "title": "Sub-teams",
    "section": "",
    "text": "Lead: Shihua Wen (Novartis)\nObjective: NA\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nZhenzhen\nXu\nFDA\n\n\nKhadija\nRantell\nMHRA\n\n\nLina\nYang\nNovartis\n\n\nShihua\nWen\nNovartis\n\n\nYeonhee\nNA\nNA"
  },
  {
    "objectID": "subteams.html#estimand",
    "href": "subteams.html#estimand",
    "title": "Sub-teams",
    "section": "Estimand",
    "text": "Estimand\nLead: Nicolas Ballarini (Novartis)\nObjective: The objective of this WG is to promote the concept of estimands and establish a harmonized estimand framework for the clinical development of Cell and Gene Therapies (CGT). Specifically, the WG’s aim is to identify and address the unique challenges posed by intercurrent events in CGT development, and formulate appropriate strategies for their handling.\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nYiran\nHu\nAbbvie\n\n\nCong\nHang\nAstellas\n\n\nAlessandro\nPrevitali\nBMS\n\n\nKhadija\nRantell\nMHRA\n\n\nAlex\nSverdlov\nNovartis\n\n\nNicolas\nBallarini\nNovartis\n\n\nShihua\nWen\nNovartis\n\n\nAvery\nMcIntosh\nPfizer"
  },
  {
    "objectID": "subteams.html#dose-finding",
    "href": "subteams.html#dose-finding",
    "title": "Sub-teams",
    "section": "Dose Finding",
    "text": "Dose Finding\nLead: Revathi Ananthakrishnan (BMS), Rong Liu (Regeneron)\nObjective: NA\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nDaniel\nLi\nBMS\n\n\nRevathi\nAnanthakrishnan\nBMS\n\n\nAlly\nHe\nCrisprtx\n\n\nAndrew\nLewandowski\nNovartis\n\n\nBambang\nAdiwijaya\nNovartis\n\n\nRong\nLiu\nRegeneron"
  },
  {
    "objectID": "subteams.html#chemistry-manufacturing-and-controls-cmc",
    "href": "subteams.html#chemistry-manufacturing-and-controls-cmc",
    "title": "Sub-teams",
    "section": "Chemistry, Manufacturing, and Controls (CMC)",
    "text": "Chemistry, Manufacturing, and Controls (CMC)\nLead: Sangwook Choi (BMS)\nObjective: To identify key CMC challenges in CGT development and to serve as key opinion leaders in CGT CMC within biopharmaceutical communities\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nSangwook\nChoi\nBMS\n\n\nBill\nPikounis\nJNJ\n\n\nJose\nRamirez\nKitepharma\n\n\nAlan\nChiang\nLyell\n\n\nLina\nYang\nNovartis"
  },
  {
    "objectID": "subteams.html#continuing-education-and-outreach",
    "href": "subteams.html#continuing-education-and-outreach",
    "title": "Sub-teams",
    "section": "Continuing Education and Outreach",
    "text": "Continuing Education and Outreach\nLead: Patricia Anderson (ICON plc)\nObjective: To promote best practices in the design and analysis of cell and gene therapy trials through knowledge sharing of current global development in the field with focus on the following:\n\nTypes of cell and gene therapies (what they are, how they work, what are the important considerations for statisticians)\nNew and updated regulatory guidance\nNew therapy approvals\n\nIndustry hot topics or safety findings (eg, secondary malignancy investigations, new safety AEs)\n\nIn addition, the subteam supports requests for short courses and other presentations as well as general outreach.\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nCong\nHang\nAstellas\n\n\nRevathi\nAnanthakrishnan\nBMS\n\n\nPatricia\nAnderson\nICON plc\n\n\nAlan\nChiang\nLyell\n\n\nKhadija\nRantell\nMHRA\n\n\nNicolas\nBallarini\nNovartis\n\n\nShihua\nWen\nNovartis"
  },
  {
    "objectID": "subteams.html#trial-design",
    "href": "subteams.html#trial-design",
    "title": "Sub-teams",
    "section": "Trial Design",
    "text": "Trial Design\nLead: Weidong Zang (Sana)\nObjective: NA\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nDaniel\nLi\nBMS\n\n\nRevathi\nAnanthakrishnan\nBMS\n\n\nZhenzhen\nXu\nFDA\n\n\nPatricia\nAnderson\nICON plc\n\n\nEvgeny\nDegtyarev\nNovartis\n\n\nNicolas\nBallarini\nNovartis"
  },
  {
    "objectID": "subteams.html#long-term-follow-up-ltfu",
    "href": "subteams.html#long-term-follow-up-ltfu",
    "title": "Sub-teams",
    "section": "Long-Term Follow Up (LTFU)",
    "text": "Long-Term Follow Up (LTFU)\nLead: Khadija Rantell (MHRA)\nObjective: NA\n\n\n\n\nFirstname\nLastname\nInstitution\n\n\n\n\nPatricia\nAnderson\nICON plc\n\n\nAlan\nChiang\nLyell\n\n\nAlex\nSverdlov\nNovartis\n\n\nShihua\nWen\nNovartis"
  }
]